nach oben

Clinical Pharmacokinetics

Erschienen in:

20.04.2021 | Review Article

Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses

verfasst von: Ibrahim El-Haffaf, Jean-Alexandre Caissy, Amélie Marsot

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly prescribed in the intensive care unit setting. Admitted patients often show large variability in treatment response due to multiple pathophysiological changes present in this population that alter the drug’s pharmacokinetics. This review summarizes the population pharmacokinetic models developed for piperacillin-tazobactam and provides comprehensive data on current dosing strategies while identifying significant covariates in critically ill patients. A literature search on the PubMed database was conducted, from its inception to July 2020. Relevant articles were retained if they met the defined inclusion/exclusion criteria. A total of ten studies, published between 2009 and 2020, were eligible. One- and two-compartment models were used in two and eight studies, respectively. The lowest estimated piperacillin clearance value was 3.12 L/h, and the highest value was 19.9 L/h. The estimations for volume of distribution varied between 11.2 and 41.2 L. Tazobactam clearance values ranged between 5.1 and 6.78 L/h, and tazobactam volume of distribution values ranged between 17.5 and 76.1 L. The most frequent covariates were creatinine clearance and body weight, each present in four studies. Almost all studies used an exponential approach for the interindividual variability. The highest variability was observed in piperacillin central volume of distribution, at a value of 75.0%. Simulations showed that continuous or extended infusion methods performed better than intermittent administration to achieve appropriate pharmacodynamic targets. This review synthesizes important pharmacokinetic elements for piperacillin-tazobactam in an intensive care unit setting. This will help clinicians better understand changes in the drug’s pharmacokinetic parameters in this specific population.

Nur mit Berechtigung zugänglich

Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012;56(11):5715–23. https://doi.org/10.1128/AAC.00937-12.CrossRefPubMedPubMedCentral

Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. https://doi.org/10.1128/CMR.00037-09.CrossRefPubMedPubMedCentral

Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010;6(8):1017–31. https://doi.org/10.1517/17425255.2010.506187.CrossRefPubMed

European Centre for Disease Prevention and Control. Antimicrobial consumption in the EU/EEA: Annual epidemiological report for 2018. 2018. https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial-consumption-EU-EEA.pdf.

Cotteret C, Vallières E, Roy H, Ovetchkine P, Longtin J, Bussières JF. Antibiotic consumption and bacterial sensitivity in a teaching hospital: a 5-year study [in French]. Arch Pediatr. 2016;23(10):1040–9. https://doi.org/10.1016/j.arcped.2016.07.004.CrossRefPubMed

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10. https://doi.org/10.1086/516284 (quiz 11-2).

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. https://doi.org/10.1186/s13054-019-2378-9.CrossRefPubMedPubMedCentral

Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. https://doi.org/10.1016/j.addr.2014.07.006.CrossRefPubMed

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, et al.; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021-1032. https://doi.org/10.1007/s00134-017-4780-6.

10.

Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51. https://doi.org/10.1097/CCM.0b013e3181961bff.CrossRefPubMed

11.

Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27–36. https://doi.org/10.1111/j.1365-2125.2011.04080.x.CrossRefPubMedPubMedCentral

12.

Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Infection Section of European Society of Intensive Care Medicine (ESICM). Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153. https://doi.org/10.1007/s00134-020-06050-1.

13.

MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38(2):284–8. https://doi.org/10.1086/379825.CrossRefPubMed

14.

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al.; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509. https://doi.org/10.1016/S1473-3099(14)70036-2.

15.

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al.; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–83. https://doi.org/10.1093/cid/ciu027.

16.

Richter DC, Frey O, Röhr A, Roberts JA, Köberer A, Fuchs T, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection. 2019;47(6):1001–11. https://doi.org/10.1007/s15010-019-01352-z.CrossRefPubMed

17.

Bloos F, Rüddel H, Thomas-Rüddel D, Schwarzkopf D, Pausch C, Harbarth S, et al.; MEDUSA study group. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med. 2017;43(11):1602-1612. htthttps://doi.org/10.1007/s00134-017-4782-4

18.

Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, et al. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents. 2013;41(2):162–6. https://doi.org/10.1016/j.ijantimicag.2012.10.002.CrossRefPubMed

19.

Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 2018;78:439–51. https://doi.org/10.1007/s40265-018-0880-z.CrossRefPubMed

20.

Roberts JA, Kirkpatrick CMJ, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011;66(2):227–31. https://doi.org/10.1093/jac/dkq449.CrossRefPubMed

21.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLOS Med.2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.

22.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother. 2014;69(1):180–9. https://doi.org/10.1093/jac/dkt304.CrossRefPubMed

23.

Bue M, Sou T, Okkels ASL, Hanberg P, Thorsted A, Friberg LE, et al. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy. Int J Infect Dis. 2020;92:133–40. https://doi.org/10.1016/j.ijid.2020.01.010.CrossRefPubMed

24.

Roberts DM, Liu X, Roberts JA, et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015. https://doi.org/10.1186/s13054-015-0818-8.CrossRefPubMedPubMedCentral

25.

Tamme K, Oselin K, Kipper K, Tasa T, Metsvaht T, Karjagin J, et al. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. Acta Anaesthesiol Scand. 2016;60(2):230–40. https://doi.org/10.1111/aas.12629.CrossRefPubMed

26.

Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, et al. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. J Antimicrob Chemother. 2016;71(6):1651–9. https://doi.org/10.1093/jac/dkv503.CrossRefPubMed

27.

Öbrink-Hansen K, Juul RV, Storgaard M, Thomsen MK, Hardlei TF, Brock B, et al. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Antimicrob Agents Chemother. 2015;59(11):7018–26. https://doi.org/10.1128/AAC.01347-15.CrossRefPubMedPubMedCentral

28.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2009;35(2):156–63. https://doi.org/10.1016/j.ijantimicag.2009.10.008.CrossRefPubMed

29.

Sukarnjanaset W, Jaruratanasirikul S, Wattanavijitkul T. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis. J Pharmacokinet Pharmacodyn. 2019;46:251–61. https://doi.org/10.1007/s10928-019-09633-8.CrossRefPubMed

30.

Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care. 2015;19(1):28. https://doi.org/10.1186/s13054-015-0750-y.CrossRefPubMedPubMedCentral

31.

Klastrup V, Thorsted A, Storgaard M, Christensen S, Friberg LE, Öbrink-Hansen K. Population pharmacokinetics of piperacillin following continuous infusion in critically Ill patients and impact of renal function on target attainment. Antimicrob Agents Chemother. 2020;64(7):e02556-e2619. https://doi.org/10.1128/AAC.02556-19.CrossRefPubMedPubMedCentral

32.

Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, et al. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 2013;69(6):1223–33. https://doi.org/10.1007/s00228-012-1413-4.CrossRefPubMed

33.

Delattre IK, Musuamba FT, Jacqmin P, Taccone FS, Laterre PF, Verbeeck RK, et al. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Clin Biochem. 2012;45(10–11):780–6. https://doi.org/10.1016/j.clinbiochem.2012.03.030.CrossRefPubMed

34.

Cies JJ, Shankar V, Schlichting C, Kuti JL. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014;33(2):168–73. https://doi.org/10.1097/INF.0b013e3182a743c7.CrossRefPubMed

35.

Akers KS, Niece KL, Chung KK, Cannon JW, Cota JM, Murray CK. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. J Trauma Acute Care Surg. 2014;77(3 Suppl 2):S163–70. https://doi.org/10.1097/TA.0000000000000191.CrossRefPubMed

36.

Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, et al. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014;58(7):4094–102. https://doi.org/10.1128/AAC.02664-14.CrossRefPubMedPubMedCentral

37.

Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, et al. Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther. 2014;96(4):438–48. https://doi.org/10.1038/clpt.2014.131.CrossRefPubMed

38.

Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, et al. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically Ill children. Antimicrob Agents Chemother. 2015;60(1):522–31. https://doi.org/10.1128/AAC.02089-15.CrossRefPubMedPubMedCentral

39.

Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, et al. Pharmacokinetics of piperacillin in critically Ill Australian indigenous patients with severe sepsis. Antimicrob Agents Chemother. 2016;60(12):7402–6. https://doi.org/10.1128/AAC.01657-16.CrossRefPubMedPubMedCentral

40.

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. Antimicrob Agents Chemother. 2017;61(3):e01276-e1316. https://doi.org/10.1128/AAC.01276-16.CrossRefPubMedPubMedCentral

41.

De Cock PAJG, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, et al. Dose optimization of piperacillin/tazobactam in critically ill children. J Antimicrob Chemother. 2017;72(7):2002–11. https://doi.org/10.1093/jac/dkx093.CrossRefPubMed

42.

Salerno S, Hornik CP, Cohen-Wolkowiez M, Smith PB, Ku LC, Kelly MS, et al., Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Use of population pharmacokinetics and electronic health records to assess piperacillin-tazobactam safety in infants. Pediatr Infect Dis J. 2017;36(9):855-859. https://doi.org/10.1097/INF.0000000000001610.

43.

Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. Int J Antimicrob Agents. 2018;51(4):594–600. https://doi.org/10.1016/j.ijantimicag.2017.12.015.CrossRefPubMed

44.

Felton TW, Ogungbenro K, Boselli E, Hope WW, Rodvold KA. Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. J Antimicrob Chemother. 2018;73(5):1340–7. https://doi.org/10.1093/jac/dkx541.CrossRefPubMed

45.

Kanji S, Roberts JA, Xie J, Alobaid A, Zelenitsky S, Hiremath S, et al. Piperacillin population pharmacokinetics in critically ill adults during sustained low-efficiency dialysis. Ann Pharmacother. 2018;52(10):965–73. https://doi.org/10.1177/1060028018773771.CrossRefPubMed

46.

Béranger A, Benaboud S, Urien S, Moulin F, Bille E, Lesage F, et al. Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. Clin Pharmacokinet. 2019;58(2):223–33. https://doi.org/10.1007/s40262-018-0682-1.CrossRefPubMed

47.

Rudnick W, Science M, Thirion DJG, et al. Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016. Antimicrob Resist Infect Control. 2020;9(1):32. https://doi.org/10.1186/s13756-020-0684-2.CrossRefPubMedPubMedCentral

48.

Fowler RA, Sabur N, Li P, Juurlink DN, Pinto R, Hladunewich MA, et al. Sex-and age-based differences in the delivery and outcomes of critical care. CMAJ. 2007;177(12):1513–9. https://doi.org/10.1503/cmaj.071112.CrossRefPubMedPubMedCentral

49.

Romo H, Amaral AC, Vincent JL. Effect of patient sex on intensive care unit survival. Arch Intern Med. 2004;164(1):61–5. https://doi.org/10.1001/archinte.164.1.61.CrossRefPubMed

50.

Reinikainen M, Niskanen M, Uusaro A, Ruokonen E. Impact of gender on treatment and outcome of ICU patients. Acta Anaesthesiol Scand. 2005;49(7):984–90. https://doi.org/10.1111/j.1399-6576.2005.00759.x.CrossRefPubMed

51.

O’Brien Z, Cass A, Cole L, et al. Sex and mortality in septic severe acute kidney injury. J Crit Care. 2019;49:70–6. https://doi.org/10.1016/j.jcrc.2018.10.017.CrossRefPubMed

52.

Sörgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med. 1994;20(Suppl 3):S14-20. https://doi.org/10.1007/BF01745246.CrossRefPubMed

53.

Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NH. Nonlinear pharmacokinetics of piperacillin in healthy volunteers–implications for optimal dosage regimens. Br J Clin Pharmacol. 2010;70(5):682–93. https://doi.org/10.1111/j.1365-2125.2010.03750.x.CrossRefPubMedPubMedCentral

54.

De Schepper PJ, Tjandramaga TB, Mullie A, Verbesselt R, van Hecken A, Verberckmoes R, et al. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother. 1982;9(Suppl B):49–57. https://doi.org/10.1093/jac/9.suppl_b.49.CrossRefPubMed

55.

Arzuaga A, Maynar J, Gascón AR, Isla A, Corral E, Fonseca F, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2020;45(2):168–76. https://doi.org/10.1177/0091270004269796.CrossRef

56.

Pistolesi V, Morabito S, Di Mario F, Regolisti G, Cantarelli C, Fiaccadori E. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019;63(8):e00583-e619. https://doi.org/10.1128/AAC.00583-19.CrossRefPubMedPubMedCentral

57.

Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing. Antibiotics (Basel). 2020;9(7):393. https://doi.org/10.3390/antibiotics9070393.CrossRefPubMedCentral

58.

Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol. 2002;22(4):320–4. https://doi.org/10.1159/000065221.CrossRefPubMed

59.

Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126. https://doi.org/10.1186/cc9091.CrossRefPubMedPubMedCentral

60.

Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137. https://doi.org/10.1186/cc10257.CrossRefPubMedPubMedCentral

61.

Liu Q, Rand K, Derendorf H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents. 2004;23(5):494–7. https://doi.org/10.1016/j.ijantimicag.2003.10.012.CrossRefPubMed

62.

Nicasio AM, VanScoy BD, Mendes RE, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro Infection Model. Antimicrob Agents Chemother. 2016;60(4):2075–80. https://doi.org/10.1128/AAC.02747-15.CrossRefPubMedPubMedCentral

63.

Kalaria SN, Gopalakrishnan M, Heil EL. A population pharmacokinetics and pharmacodynamic approach to optimize tazobactam activity in critically ill patients. Antimicrob Agents Chemother. 2020;64(3):e02093-e2119. https://doi.org/10.1128/AAC.02093-19.CrossRefPubMedPubMedCentral

64.

Komuro M, Maeda T, Kakuo H, Matsushita H, Shimada J. Inhibition of the renal excretion of tazobactam by piperacillin. J Antimicrob Chemother. 1994;34(4):555–64. https://doi.org/10.1093/jac/34.4.555.CrossRefPubMed

65.

Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320–32. https://doi.org/10.1592/phco.26.9.1320.

66.

Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock–does the dose matter? Crit Care. 2009;13(3):214. https://doi.org/10.1186/cc7774.CrossRefPubMedPubMedCentral

67.

Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2(1):37. https://doi.org/10.1186/2110-5820-2-37.CrossRefPubMedPubMedCentral

68.

Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2):272–82. https://doi.org/10.1093/cid/cis857.CrossRefPubMed

69.

Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care. 2008;14(4):390–6. https://doi.org/10.1097/MCC.0b013e3283021b3a.CrossRefPubMed

70.

Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):430. https://doi.org/10.1186/s12879-020-05149-6.CrossRefPubMedPubMedCentral

71.

Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al., BLING II Investigators for the ANZICS Clinical Trials Group *. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–305. https://doi.org/10.1164/rccm.201505-0857OC.

72.

Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–45. https://doi.org/10.1007/s00134-015-4188-0(Epub2016).CrossRefPubMed

73.

Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, et al. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc. 2019;21(1):63–8.PubMed

Titel: Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
verfasst von: Ibrahim El-Haffaf
Jean-Alexandre Caissy
Amélie Marsot
Publikationsdatum: 20.04.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 7/2021
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-021-01013-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance